Acelrx Pharmaceuticals Inc EV/EBIT
What is the EV/EBIT of Acelrx Pharmaceuticals Inc?
The EV/EBIT of Acelrx Pharmaceuticals Inc is N/A
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc
What does Acelrx Pharmaceuticals Inc do?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Companies with ev/ebit similar to Acelrx Pharmaceuticals Inc
- iCetana has EV/EBIT of N/A
- Beyond Meat Inc has EV/EBIT of N/A
- Conscience Capital has EV/EBIT of N/A
- Heliospectra AB has EV/EBIT of N/A
- Titan Mining has EV/EBIT of N/A
- Vaxart has EV/EBIT of N/A
- Acelrx Pharmaceuticals Inc has EV/EBIT of N/A
- General Moly has EV/EBIT of N/A
- Biotricity has EV/EBIT of N/A
- Fitbit A Dl ,0001 has EV/EBIT of N/A
- Huntsman Exploration Inc has EV/EBIT of N/A
- Signify Health has EV/EBIT of N/A
- Monaker Inc has EV/EBIT of N/A